The CEO of Switzerland’s big pharma company Roche, Severin Schwan, has categorized the launch of the new multiple sclerosis therapy Ocrevus (ocrelizumab) in the first half of 2017 as “particularly pleasing,” a “phenomenal start,” and “even above our own expectations.”
There was strong underlying demand for Ocrevus across its two indications, relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis,...








